These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35983608)

  • 21. Computer-assisted discovery of safe and effective DprE1/ aaRSs Inhibitors against TB utilizing Drug Repurposing approach.
    Imran M; Abida ; Alotaibi NM; Thabet HK; Alruwaili JA; Asdaq SMB; Eltaib L; Kamal M; Alshammari ABH; Alshammari AMA; Alshehri A
    J Infect Public Health; 2023 Apr; 16(4):554-572. PubMed ID: 36812878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Muthiah I; Rajendran K; Dhanaraj P; Vallinayagam S
    J Biomol Struct Dyn; 2021 Aug; 39(13):4807-4815. PubMed ID: 32580684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing the effect of NEK7 and cofactor interactions on dynamics of NLRP3 monomer using molecular simulation.
    El-Sayed S; Freeman S; Bryce RA
    Protein Sci; 2022 Oct; 31(10):e4420. PubMed ID: 36173167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
    Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F
    Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
    Shoaib TH; Ibraheem W; Abdelrahman M; Osman W; Sherif AE; Ashour A; Ibrahim SRM; Ghazawi KF; Miski SF; Almadani SA; ALsiyud DF; Mohamed GA; Alzain AA
    PLoS One; 2023; 18(8):e0289887. PubMed ID: 37578958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination strategy of structure-based virtual screening, MM-GBSA, cross docking, molecular dynamics and metadynamics simulations used to investigate natural compounds as potent and specific inhibitors of tumor linked human carbonic anhydrase IX.
    Chahal V; Kakkar R
    J Biomol Struct Dyn; 2023; 41(12):5465-5480. PubMed ID: 35735269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.
    Srisongkram T; Weerapreeyakul N
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy.
    Shahab M; Al-Madhagi H; Zheng G; Zeb A; Alasmari AF; Alharbi M; Alasmari F; Khan MQ; Khan M; Wadood A
    Sci Rep; 2023 Sep; 13(1):14466. PubMed ID: 37660065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing FDA-approved compounds to target JAK2 for colon cancer treatment.
    Chandrasekhar B; Gor R; Ramalingam S; Thiagarajan A; Sohn H; Madhavan T
    Discov Oncol; 2024 Jun; 15(1):226. PubMed ID: 38869738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
    Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
    Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.
    Rahman MM; Saha T; Islam KJ; Suman RH; Biswas S; Rahat EU; Hossen MR; Islam R; Hossain MN; Mamun AA; Khan M; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6231-6241. PubMed ID: 32692306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Nek7-interactor RGS2 is required for mitotic spindle organization.
    de Souza EE; Hehnly H; Perez AM; Meirelles GV; Smetana JH; Doxsey S; Kobarg J
    Cell Cycle; 2015; 14(4):656-67. PubMed ID: 25664600
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug repurposing against the RNA-dependent RNA polymerase domain of dengue serotype 3 by virtual screening and molecular dynamics simulations.
    Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Jul; 41(11):5152-5165. PubMed ID: 35642087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.